These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11795651)

  • 1. Factors influencing remission phase in children with type 1 diabetes mellitus.
    Büyükgebiz A; Cemeroglu AP; Böber E; Mohn A; Chiarelli F
    J Pediatr Endocrinol Metab; 2001; 14(9):1585-96. PubMed ID: 11795651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual beta-cell function and spontaneous clinical remission in type 1 diabetes mellitus: the role of puberty.
    Bonfanti R; Bognetti E; Meschi F; Brunelli A; Riva MC; Pastore MR; Calori G; Chiumello G
    Acta Diabetol; 1998 Jul; 35(2):91-5. PubMed ID: 9747961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus.
    Ludwig B; Barthel A; Reichel A; Block NL; Ludwig S; Schally AV; Bornstein SR
    Vitam Horm; 2014; 95():195-222. PubMed ID: 24559919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type I diabetes mellitus: a predictable autoimmune disease with interindividual variation in the rate of beta cell destruction.
    Dotta F; Eisenbarth GS
    Clin Immunol Immunopathol; 1989 Jan; 50(1 Pt 2):S85-95. PubMed ID: 2642771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predicting remission in type I diabetes.
    Pelkonen R; Aro A
    Ann Clin Res; 1984; 16(2):94-7. PubMed ID: 6380392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding childhood diabetes mellitus: new pathophysiological aspects.
    Grulich-Henn J; Klose D
    J Inherit Metab Dis; 2018 Jan; 41(1):19-27. PubMed ID: 29247329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Customized cell-based treatment options to combat autoimmunity and restore beta-cell function in type 1 diabetes mellitus: current protocols and future perspectives.
    Fändrich F; Ungefroren H
    Adv Exp Med Biol; 2010; 654():641-65. PubMed ID: 20217518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention.
    Pozzilli P; Di Mario U
    Diabetes Care; 2001 Aug; 24(8):1460-7. PubMed ID: 11473087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The natural history of diabetes with respect to disorders of insulin function].
    Dorner M; Pinget M; Brogard JM; Sapin R; Paris-Bockel D; Levy P; Jung C
    Journ Annu Diabetol Hotel Dieu; 1984; ():51-71. PubMed ID: 6399540
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting autoimmune diabetes with gene therapy.
    Giannoukakis N; Rudert WA; Robbins PD; Trucco M
    Diabetes; 1999 Nov; 48(11):2107-21. PubMed ID: 10535443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics, and time course of pancreatic beta-cell function and glutamic acid decarboxylase antibodies in Thai patients with adult-onset Type 1 diabetes: distinction between patients of rapid- and slow-onset.
    Rattarasarn C; Diosdado MA
    Horm Metab Res; 1999 May; 31(5):311-6. PubMed ID: 10422726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association of Autoimmune Diseases with Type 1 Diabetes Mellitus in Children Depends Also by the Length of Partial Clinical Remission Phase (Honeymoon).
    Ozen G; Zanfardino A; Confetto S; Piscopo A; Casaburo F; Tinto N; Iafusco F; Ozen G; Miraglia Del Giudice E; Tasar MA; Yilmaz A; Iafusco D
    Int J Endocrinol; 2020; 2020():2630827. PubMed ID: 32215008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-cell function recovery is not the only factor responsible for remission in type I diabetics: evaluation of C-peptide secretion in diabetic children after first metabolic recompensation and at partial remission phase.
    Schober E; Schernthaner G; Frisch H; Fink M
    J Endocrinol Invest; 1984 Oct; 7(5):507-12. PubMed ID: 6392401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does partial preservation of residual beta-cell function justify immune intervention in recent onset Type I diabetes?
    Kolb H; Gale EA
    Diabetologia; 2001 Oct; 44(10):1349-53. PubMed ID: 11692186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The period of initial remission in insulin-dependent diabetes. Effect of optimized insulin therapy].
    Vague P; Vialettes B; Lassmann V; Moulin JP
    Journ Annu Diabetol Hotel Dieu; 1984; ():73-84. PubMed ID: 6399541
    [No Abstract]   [Full Text] [Related]  

  • 16. Autoimmunity to islet cells in diabetes mellitus.
    Powers AC; Eisenbarth GS
    Annu Rev Med; 1985; 36():533-44. PubMed ID: 3888064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DiaPep277® and immune intervention for treatment of type 1 diabetes.
    Schloot NC; Cohen IR
    Clin Immunol; 2013 Dec; 149(3):307-16. PubMed ID: 24090708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.
    Simmons K; Michels AW
    Rheum Dis Clin North Am; 2014 Nov; 40(4):797-811. PubMed ID: 25437293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organ-specific autoimmunity and HLA-DR antigens as markers for beta-cell destruction in patients with type II diabetes.
    Groop L; Miettinen A; Groop PH; Meri S; Koskimies S; Bottazzo GF
    Diabetes; 1988 Jan; 37(1):99-103. PubMed ID: 3275559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future trends in diabetes management.
    George CM
    Nephrol Nurs J; 2009; 36(5):477-83. PubMed ID: 19856809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.